JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$5.47B |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.17B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$2.05B |
| 4 |
Amazon
AMZN
|
+$1.96B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.72B |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$1.31B |
| 3 |
UnitedHealth
UNH
|
+$1.26B |
| 4 |
Automatic Data Processing
ADP
|
+$1.17B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.08B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.28% |
| 2 | Technology | 17.17% |
| 3 | Healthcare | 10.79% |
| 4 | Financials | 9.36% |
| 5 | Consumer Discretionary | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2201
Trustmark
TRMK
$2.64B
| $9.96M | ﹤0.01% |
403,189
+55,951
| +16% | +$1.65M |
2013 Q2
39 quarters
|
|
2202
iShares JPMorgan Broad USD Emerging Markets Bond ETF
BEMB
$40.4M
| $9.94M | ﹤0.01% |
+194,000
| New | +$9.8M |
2023 Q1
0 quarters
|
|
2203
VanEck Biotech ETF
BBH
$480M
| $9.94M | ﹤0.01% |
61,302
-12,841
| -17% | -$2.08M |
2022 Q2
3 quarters
|
|
|
K
2204
CALL
DELISTED
Kellanova
K
| $9.9M | ﹤0.01% |
157,407
+149,739
| +1,953% | +$9.46M |
2021 Q1
8 quarters
|
|
2205
GoPro
GPRO
$281M
| $9.89M | ﹤0.01% |
1,965,363
-102,155
| -5% | -$552K |
2014 Q3
34 quarters
|
|
2206
CALL
Enterprise Products Partners
EPD
$79.5B
| $9.88M | ﹤0.01% |
381,600
-294,100
| -44% | -$7.55M |
2021 Q2
7 quarters
|
|
2207
AMN Healthcare
AMN
$1.43B
| $9.88M | ﹤0.01% |
119,088
+13,330
| +13% | +$1.25M |
2013 Q2
39 quarters
|
|
2208
First Trust North American Energy Infrastructure Fund
EMLP
$3.99B
| $9.87M | ﹤0.01% |
370,743
+89,344
| +32% | +$2.4M |
2013 Q2
39 quarters
|
|
2209
CALL
Nutrien
NTR
$33.5B
| $9.85M | ﹤0.01% |
133,400
-776,900
| -85% | -$59.9M |
2022 Q3
2 quarters
|
|
2210
Arcus Biosciences
RCUS
$3.15B
| $9.85M | ﹤0.01% |
539,995
+25,084
| +5% | +$479K |
2018 Q1
20 quarters
|
|
|
CHCT
2211
Community Healthcare Trust
CHCT
$383M
| $9.85M | ﹤0.01% |
269,028
+141,996
| +112% | +$5.54M |
2016 Q1
28 quarters
|
|
2212
Fate Therapeutics
FATE
$291M
| $9.84M | ﹤0.01% |
1,725,729
+258,725
| +18% | +$1.56M |
2017 Q1
24 quarters
|
|
2213
SiTime
SITM
$21.4B
| $9.83M | ﹤0.01% |
69,132
+10,269
| +17% | +$1.26M |
2020 Q1
12 quarters
|
|
2214
CALL
AT&T
T
$166B
| $9.83M | ﹤0.01% |
510,800
-882,996
| -63% | -$16.9M |
2014 Q3
34 quarters
|
|
2215
CALL
Gaming and Leisure Properties
GLPI
$11B
| $9.79M | ﹤0.01% |
188,100
-498,100
| -73% | -$26M |
2022 Q4
1 quarter
|
|
2216
CALL
Best Buy
BBY
$18.3B
| $9.78M | ﹤0.01% |
125,000
-47,200
| -27% | -$3.89M |
2021 Q2
7 quarters
|
|
2217
Albany International
AIN
$1.69B
| $9.76M | ﹤0.01% |
109,246
-2,828
| -3% | -$285K |
2013 Q2
39 quarters
|
|
|
ARGO
2218
DELISTED
Argo Group International Holdings, Ltd.
ARGO
| $9.75M | ﹤0.01% |
332,929
+264,412
| +386% | +$7.49M |
2013 Q2
39 quarters
|
|
2219
Grid Dynamics Holdings
GDYN
$636M
| $9.74M | ﹤0.01% |
849,729
+73,423
| +9% | +$862K |
2020 Q2
11 quarters
|
|
2220
Progress Software
PRGS
$1.52B
| $9.71M | ﹤0.01% |
169,018
+30,594
| +22% | +$1.71M |
2013 Q2
39 quarters
|
|
|
CGAU
2221
Centerra Gold
CGAU
$4.22B
| $9.66M | ﹤0.01% |
1,492,950
+70,260
| +5% | +$438K |
2021 Q2
7 quarters
|
|
|
CTLT
2222
CALL
DELISTED
CATALENT, INC.
CTLT
| $9.64M | ﹤0.01% |
+146,700
| New | +$9.06M |
2023 Q1
0 quarters
|
|
|
JPSV
2223
JPMorgan Active Small Cap Value ETF
JPSV
$25.9M
| $9.63M | ﹤0.01% |
+200,000
| New | +$9.5M |
2023 Q1
0 quarters
|
|
2224
Coty
COTY
$2.4B
| $9.63M | ﹤0.01% |
798,728
-84,889
| -10% | -$898K |
2013 Q4
37 quarters
|
|
2225
Evertec
EVTC
$1.74B
| $9.6M | ﹤0.01% |
284,370
+14,475
| +5% | +$508K |
2013 Q2
39 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2023 Portfolio in Review
As of Q1 2023, JP Morgan Chase held 7,579 positions worth $821B, up 8.2% from $759B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q1 2023 filing shows 751 new, 3,314 increased, 2,056 reduced and 652 closed positions. Its largest new stake was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M. The largest sale was Eli Lilly, an estimated $1.72B.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, up from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q1 2023 buy was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q1 2023, an estimated $5.47B increase.
- JP Morgan Chase's biggest Q1 2023 reduction was Eli Lilly, cutting an estimated $1.72B.
- JP Morgan Chase fully exited IAA, Inc. Common Stock in Q1 2023, selling an estimated $155M.
- JP Morgan Chase's ten largest holdings make up 17% of its $821B portfolio in Q1 2023.
- JP Morgan Chase opened 751 new positions and closed 652 in Q1 2023.
- JP Morgan Chase's portfolio value rose 8.2% quarter-over-quarter to $821B.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.